O96017 (CHK2_HUMAN) Homo sapiens (Human)

Serine/threonine-protein kinase Chk2 UniProtKBInterProSTRINGInteractive Modelling

543 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9; Isoform 10; Isoform 11; Isoform 12; Isoform 13); 1 identical sequence: Pan troglodytes: K7D8Y1

Available Structures

38 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of the mammalian MDC1 FHA domain complexed with CHK2 pThr68 peptide
3va4
 Heteromer
Q5PSV9; 		66-73
Assess
Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase
3i6u
homo-2-mer89-501
Assess
Structure and Activation Mechanism of the CHK2 DNA-Damage Checkpoint Kinase
3i6w
homo-2-mer92-501
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdi
homo-2-mer210-515
2×HAU; 2×NO3; 2×CL; 14×EDO;
Assess
CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4a9u
homo-2-mer210-513
2×NO3; 18×EDO; 2×A9U; 2×CL;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdh
homo-2-mer210-513
2×NO3; 2×WVI; 6×EDO; 2×CL;
Assess
CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4a9t
homo-2-mer210-513
2×A9T; 2×NO3; 6×EDO;
Assess
CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4a9r
homo-2-mer210-513
2×NO3; 2×RU5; 2×EDO;
Assess
CRYSTAL STRUCTURE OF HUMAN CHK2 IN COMPLEX WITH BENZIMIDAZOLE CARBOXAMIDE INHIBITOR
4a9s
homo-2-mer211-513
2×NO3; 2×RU9;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdd
homo-2-mer210-512
6×EDO; 2×Z0O; 2×NO3;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdf
homo-2-mer210-512
2×H3R; 2×NO3; 4×EDO;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdg
homo-2-mer210-512
2×P3J; 2×NO3; 2×EDO; 2×CL;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdj
homo-2-mer211-513
2×Z2M; 2×NO3;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdk
homo-2-mer211-513
2×RQQ; 2×NO3; 6×EDO;
Assess
Crystal Structure of Chk2 in complex with an inhibitor
2xbj
homo-2-mer211-512
2×XBJ; 2×MG; 4×NO3;
Assess
Structure of a small molecule inhibitor with the kinase domain of Chk2
2xm9
homo-2-mer211-512
2×LWH; 2×NO3;
Assess
Crystal Structure of Checkpoint Kinase 2 in complex with Inhibitor PV1531
2ycf
homo-2-mer210-510
2×YCF; 2×MG; 2×NO3;
Assess
Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel Chk2 inhibi…
2w7x
homo-2-mer210-510
2×D1A; 2×MG; 2×NO3; 4×EDO;
Assess
Crystal structure of checkpoint kinase 2 in complex with PV788
2ycs
homo-2-mer210-510
2×NXP; 2×NO3;
Assess
Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1322
2yiq
homo-2-mer211-510
2×YIQ; 2×NO3;
Assess
Crystal structure of checkpoint kinase 2 in complex with inhibitor PV1115
2ycq
homo-2-mer211-510
2×UPX; 2×NO3;
Assess
Structural analysis of checkpoint kinase 2 in complex with inhibitor PV1352
2yir
homo-2-mer210-509
2×YIR; 2×NO3;
Assess
Structural analysis of checkpoint kinase 2 in complex with PV1162, a novel inhibitor
2yit
homo-2-mer211-510
2×YIT; 2×NO3;
Assess
Crystal structure of checkpoint kinase 2 in complex with inhibitor PV976
2ycr
homo-2-mer211-510
2×HCW; 2×NO3;
Assess
Structural analysis of checkpoint kinase 2 (Chk2) in complex with inhibitor PV1533
2xk9
homo-2-mer211-510
2×XK9;
Assess
Crystal structure of human Chk2 in complex with ADP
2cn5
homo-2-mer209-504
2×CL; 4×MG; 2×NO3; 2×ADP;
Assess
Co-crystal structure of a small molecule inhibitor bound to the kinase domain of Chk2
2xm8
homo-2-mer211-503
2×B4W;
Assess
Crystal structure of human Chk2 in complex with debromohymenialdisine
2cn8
homo-2-mer212-503
2×MG; 2×NO3; 2×DBQ;
Assess
CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2wtj
monomer209-512
1×WTJ; 2×NO3; 4×EDO;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdb
monomer210-513
1×NO3; 9×EDO; 1×ODO;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bde
monomer210-513
1×NO3; 4×EDO; 1×CWS;
Assess
CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2wti
monomer210-512
1×WTI; 2×NO3; 2×EDO;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bda
monomer210-512
1×NO3; 7×EDO; 1×VFB; 1×CL;
Assess
Crystal structure of Chk2 in complex with an inhibitor
2wtd
monomer210-512
1×ZZK; 1×NO3; 3×EDO;
Assess
Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)
4bdc
monomer210-512
1×ODH; 1×NO3; 1×CL; 1×EDO;
Assess
CRYSTAL STRUCTURE OF CHK2 IN COMPLEX WITH AN INHIBITOR
2wtc
monomer211-512
1×VGM; 1×NO3;
Assess
Crystal structure of Chk2 in complex with NSC 109555, a specific inhibitor
2w0j
monomer210-510
1×ZAT; 1×NO3;
Assess
FHA domain from human Chk2 kinase in complex with a synthetic phosphopeptide
1gxc
monomer92-207
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3i6w.1.Ahomo-2-mer0.7992-501
99.77
Assess
4wb7.2.Amonomer0.67215-518
1×ZN;35.82
Assess

18 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23i6w.3.Bmonomer0.6492-224
86.93
Assess
Isoform 32cn8.1.Bmonomer0.66107-122
100.00
Assess
Isoform 42w7x.1.Bhomo-2-mer0.81119-419
2×D1A; 2×MG;100.00
Assess
Isoform 44m84.1.Amonomer0.68123-400
39.55
Assess
Isoform 53i6w.1.Ahomo-2-mer0.8492-200
98.47
Assess
Isoform 63i6w.1.Ahomo-2-mer0.7092-160
88.89
Assess
Isoform 73i6w.1.Ahomo-2-mer0.7492-336
99.63
Assess
Isoform 83i6w.1.Ahomo-2-mer0.7592-288
96.79
Assess
Isoform 93i6w.1.Ahomo-2-mer0.7492-544
99.77
Assess
Isoform 94wb7.1.Amonomer0.66258-560
1×ZN;35.59
Assess
Isoform 103i6w.1.Ahomo-2-mer0.5692-136
95.52
Assess
Isoform 116ayw.1.Amonomer0.6965-173
40.00
Assess
Isoform 112xk9.1.Amonomer0.6663-192
93.38
Assess
Isoform 112oza.1.Amonomer0.5564-172
38.68
Assess
Isoform 123i6w.1.Ahomo-2-mer0.7692-472
99.76
Assess
Isoform 128guw.1.Ahomo-3-mer0.60202-457
32.64
Assess
Isoform 132ycf.1.Bhomo-2-mer0.821-289
2×YCF; 2×MG;100.00
Assess
Isoform 135dvr.1.Amonomer0.672-268
40.15
Assess